文献速递肝病

无创检查在MASLD不同年龄、2型糖尿病和肥胖亚组中的诊断准确性:跨国研究

Diagnostic Accuracy of Noninvasive Tests for Metabolic Dysfunction-Associated Steatotic Liver Disease Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-01-29

该跨国研究分析41国18759例活检确诊MASLD成人,评估FIB-4、LSM和Agile-3+对进展期纤维化(F3-F4)的诊断表现。进展期纤维化占37%;FIB-4准确性随年龄增长及中年T2D患者中下降,LSM在肥胖尤其重度肥胖中有所降低;年龄和T2D特异FIB-4切点差异大,LSM切点随BMI变化。

要点

  • LSM在肥胖及重度肥胖(BMI>35 kg/m2)中诊断表现中度至明显降低。
  • LSM切点随BMI调整:非肥胖至重度肥胖灵敏度80%对应8.8至11.0 kPa。

核心结论

  • MASLD无创检查对进展期纤维化的准确性受年龄、T2D和肥胖影响。
  • 年龄调整FIB-4阈值可能改善风险分层,影像学及复合无创检查表现更一致。

研究设计与样本

  • 跨国队列研究,纳入41个国家18759例活检确诊MASLD成人。
  • 评估FIB-4、LSM和Agile-3+对进展期纤维化(F3-F4)的诊断AUC,并按年龄、性别、T2D、肥胖和饮酒分层。

主要发现

  • 进展期纤维化占37%。
  • 汇总AUC:FIB-4为0.79,LSM为0.83,Agile-3+为0.86。
  • LSM表现跨T2D状态稳定,但在肥胖及重度肥胖(BMI>35 kg/m2)中中度至明显降低。
  • 性别和饮酒对AUC影响极小。

关键数值与推荐

  • 为维持预设准确性(灵敏度或特异度),年龄和T2D特异FIB-4切点差异显著。
  • LSM切点随BMI不同:灵敏度80%对应切点为瘦者8.8 kPa、超重9.0 kPa、肥胖9.6 kPa、重度肥胖11.0 kPa。

临床怎么用

  • 对老年和中年T2D的MASLD患者解读FIB-4时应考虑年龄调整阈值。
  • 肥胖尤其重度肥胖患者中,LSM诊断进展期纤维化需采用BMI相应切点。
  • 影像学及复合无创检查(LSM和Agile-3+)在不同亚组中表现更一致,可优先考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Noninvasive tests (NITs) are widely used to risk-stratify patients with metabolic dysfunction-associated steatotic liver disease (MASLD); however, their performance may vary according to patient characteristics. We evaluated the accuracy of NITs in a large, multinational MASLD cohort across select subpopulations. METHODS: We analyzed 18,759 adults with biopsy-confirmed MASLD from 41 countries. NITs included FIB-4, liver stiffness measurement (LSM), and Agile-3+. Diagnostic performance for advanced fibrosis (F3-F4) was measured using areas under the curve (AUCs) across subgroups defined by age, sex, type 2 diabetes (T2D), obesity, and alcohol use. Subgroup-specific cutoffs were derived. RESULTS: Advanced fibrosis was present in 37% of patients. Pooled AUCs were 0.79 for FIB-4, 0.83 for LSM, and 0.86 for Agile-3+. FIB-4 accuracy declined with age (AUC 0.70 in ≥65 years vs 0.79 in <65 years, P < .0001) and in middle-aged patients with T2D. The LSM performance remained stable across T2D status but was moderately reduced in patients with obesity and, more profoundly, morbid obesity (body mass index [BMI] >35 kg/m2). Sex and alcohol use had minimal impact on AUCs. Age- and T2D-specific FIB-4 cutoffs varied substantially to maintain predefined accuracy (sensitivity or specificity). The cutoffs for LSM also differed based on patients' BMI, with lower diagnostic cutoffs for advanced fibrosis required in nonobese MASLD (sensitivity 80%: 8.8 kPa in lean, 9.0 kPa overweight, 9.6 kPa in obesity, 11.0 kPa in morbid obesity). CONCLUSIONS: Accuracy of NITs for advanced fibrosis in MASLD is influenced by age, T2D, and obesity. Age-adjusted FIB-4 thresholds may enhance risk stratification. Imaging-based and composite NITs (LSM and Agile-3+) provide more consistent performance across MASLD subpopulations.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, de Avila L, Petta S, et al. Diagnostic Accuracy of Noninvasive Tests for Metabolic Dysfunction-Associated Steatotic Liver Disease Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study. Clin Gastroenterol Hepatol. 2026. PMID: 41616900. doi:10.1016/j.cgh.2026.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。